Based on the ILD which has been well controlled, the attending doctor suggested to choose furmonertinib (80 mg per day, targeted to the EGFR Ex19del mutation) on 19 March 2024, and follow-up for 1 month showed that the patient did not feel any discomfort. Here, EGFR is linked to interstitial lung disease.